MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
MediWound Ltd. (Nasdaq: MDWD) announced it will release its financial results for Q1 2021 on May 5, 2021, at 7:00 AM ET. A conference call and webcast will follow at 8:30 AM ET to discuss results and provide corporate updates. The company specializes in biopharmaceuticals for tissue repair and regeneration. Its product NexoBrid has been marketed in the EU and submitted for FDA review, with a PDUFA date set for June 29, 2021. Also in development are EscharEx for chronic wound treatment and MWPC005 for non-melanoma skin cancer.
- Scheduled Q1 2021 financial results release for May 5, 2021.
- NexoBrid is currently marketed in the EU and supports the FDA BLA submission.
- Positive results from Phase 2 studies for EscharEx, demonstrating safety and efficacy.
- Pending FDA approval for NexoBrid with a crucial PDUFA date approaching.
YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first quarter ended March 31, 2021 at 7:00 am Eastern Time on Wednesday, May 5, 2021.
Following the release, MediWound's management will host a conference call and live webcast on Wednesday, May 5, 2021 at 8:30 am Eastern Time to discuss the financial results and provide corporate update, and to answer questions. Dial-in and call details are as follows:
| Conference Call & Webcast Details | |
| Toll-Free: | 877-602-7189 |
| Israel Toll-Free: | 1 809 315 362 |
| International: | 678-894-3057 |
| Conference ID: | 3496059 |
| Webcast: | https://edge.media-server.com/mmc/p/7zehu5pu |
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.
About MediWound Ltd.
MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Our strategy is centered around our validated enzymatic platform technology, focused on next-generation bio-active therapies for burn and wound care and biological medicinal products for tissue repair.
NexoBrid®, our first commercialized biological product for non-surgical and rapid eschar removal of deep, partial and full-thickness thermal burns without harming viable tissue, is currently marketed in the European Union and other International markets. On June 29, 2020, a biologics license application (BLA) was submitted to the U.S. FDA and was assigned a Prescription Drug User Fee Act (PDUFA) target date of June 29, 2021. NexoBrid is supported by U.S. Biomedical Advanced Research and Development Authority (BARDA).
EscharEx®, our next-generation bioactive topical therapeutic under development in the U.S. for debridement of chronic and hard to heal wounds. In two Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.
MediWound’s third innovative product candidate, MWPC005, is a topical drug under development for the treatment of non-melanoma skin cancer.
Committed to innovation, we are dedicated to improving quality of care and patient lives. For more information, please visit www.mediwound.com.
| Contacts: | |
| Boaz Gur-Lavie | Jeremy Feffer |
| Chief Financial Officer | Managing Director, LifeSci Advisors |
| MediWound Ltd. | 212-915-2568 |
| ir@mediwound.com | jeremy@lifesciadvisors.com |
FAQ
When will MediWound release its financial results for Q1 2021?
What time is the conference call for MediWound's Q1 results?
What is the symbol for MediWound on the stock market?
What is the PDUFA date for NexoBrid?
What products is MediWound currently developing?
